FLT3 and acute myeloid leukemia: These preclinical observations of synergistic activity of venetoclax and FLT3 inhibition were subsequently evaluated in a phase 1b clinical trial of venetoclax + gilteritinib in patients with relapsed/refractory FLT3-mutated AML [54].